{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:17:08Z","timestamp":1783138628427,"version":"3.54.6"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.2169\/internalmedicine.6140-25","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:07:34Z","timestamp":1764194854000},"page":"1799-1804","source":"Crossref","is-referenced-by-count":1,"title":["Selpercatinib-induced Acalculous Cholecystitis in an Elderly Patient with RET Fusion-positive Non-small Cell Lung Cancer"],"prefix":"10.2169","volume":"65","author":[{"given":"Takeru","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Sasano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzuka","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takigawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 383: 813-824, 2020."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gautschi O, Park K, Solomon BJ, et al. Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 Phase I\/II trial. J Clin Oncol 43: 1758-1764, 2025.","DOI":"10.1200\/JCO-24-02076"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med 389: 1839-1850, 2023.","DOI":"10.1056\/NEJMoa2309457"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hotta K, Ueoka H, Kiura K, et al. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 44: 717-722, 2005.","DOI":"10.1080\/02841860500256215"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bedas A, Peled N, Maimon Rabinovich N, et al. Efficacy and safety of ALK tyrosine kinase inhibitors in elderly patients with advanced ALK-positive non-small cell lung cancer: findings from the real-life cohort. Oncol Res Treat 42: 275-282, 2019.","DOI":"10.1159\/000499086"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Barie PS, Eachempati SR. Acute acalculous cholecystitis. Gastroenterol Clin North Am 39: 343-357, 2010.","DOI":"10.1016\/j.gtc.2010.02.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245, 1981.","DOI":"10.1038\/clpt.1981.154"},{"key":"8","unstructured":"8. World Health Organization (WHO), Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment [Internet]. [cited 2025 Apr 16]. Available from: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kinoshita T, Okuma Y, Sasahara G, et al. Three cases of acute cholangitis in patients with metastatic thyroid cancer treated with lenvatinib. J Jpn Soc Head Neck Surg 28: 329-333, 2018 (in Japanese with English abstract).","DOI":"10.5106\/jjshns.28.329"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. da Fonseca LG, Barroso-Sousa R, Sabbaga J, Hoff PM. Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Pract 4: 635, 2014.","DOI":"10.4081\/cp.2014.635"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Di Stefano M, Colombo C, De Leo S, et al. High prevalence and conservative management of acute cholecystitis during lenvatinib for advanced thyroid cancer. Eur Thyroid J 10: 314-322, 2021.","DOI":"10.1159\/000510369"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ishigaki K, Hamada T, Nakai Y, et al. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma. Clin J Gastroenterol 13: 568-571, 2020.","DOI":"10.1007\/s12328-020-01116-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lu W, Tang B, Guo Q, Zhao Z, Liu L. Cholecystitis and cholangitis associated with lenvatinib: a pharmacovigilance study. Br J Clin Pharmacol 89: 579-581, 2023.","DOI":"10.1111\/bcp.15243"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sanda M, Tamai H, Deguchi H, et al. Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. ISRN Gastroenterol 2011: 201529, 2011.","DOI":"10.5402\/2011\/201529"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ramos HE, Hecht F, Berdelou A, et al. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. Endocrine 7: 434-442, 2021.","DOI":"10.1007\/s12020-020-02426-x"},{"key":"16","unstructured":"16. Eli Lilly Canada. RETEVMO<sup>\u00ae<\/sup> product monograph. Toronto, Mar 2, 2023 [Internet]. [cited 2025 Apr 16]. Available from: https:\/\/pi.lilly.com\/ca\/retevmo-ca-pm.pdf"},{"key":"17","first-page":"131","author":"HJ Hoe","year":"2025","unstructured":"17. Hoe HJ, Solomon BJ. Treatment of non-small cell lung cancer with RET rearrangements. Cancer 131, 2025.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29: 1869-1876, 2018.","DOI":"10.1093\/annonc\/mdy137"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med 28: 1640-1645, 2022.","DOI":"10.1038\/s41591-022-01931-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol 22: 959-969, 2021.","DOI":"10.1016\/S1470-2045(21)00247-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Liu D, van der Walt JS. Population pharmacokinetics modeling of selpercatinib to support posology in pediatric patients with RET-altered metastatic thyroid cancer or solid tumors. CPT Pharmacometrics Syst Pharmacol 14: 1848-1856, 2025.","DOI":"10.1002\/psp4.70042"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001. J Thorac Oncol 17: 768-778, 2022.","DOI":"10.1016\/j.jtho.2022.02.004"},{"key":"23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1186\/s12885-024-13250-1","volume":"24","author":"J Qian","year":"2024","unstructured":"23. Qian J, Zhang S, Jiang C. Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC Cancer 24: 1486, 2024.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6140-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:28:50Z","timestamp":1783135730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6140-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6140-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"6140-25"}}